SB3788 amends 21 U.S.C. 352(b) to force greater supply‑chain transparency on drug labeling. The bill requires finished drug labels (and labels/certificates of analysis for active pharmaceutical ingredients) to identify the original manufacturer of each API and the finished product by name, place of business, and a unique facility identifier (UFI), or to provide a barcode/QR/link to a searchable electronic portal containing that information.
It also directs manufacturers to make the same information available in package inserts or in paper on request, defines “original manufacturer,” and directs the Secretary of Health and Human Services to issue implementing regulations.
The change is explicitly practical: firms can either put the required facts on the label or link to a searchable portal. The bill also amends the Tariff Act of 1930 to exempt finished drug products that comply with these labeling rules from standard country‑of‑origin marking requirements.
The result is stronger traceability for recalls and investigations, but also new labeling, recordkeeping, and confidentiality pressures for manufacturers, contract packagers, and foreign API suppliers.
At a Glance
What It Does
Requires drug labeling (finished products and APIs) to identify the original manufacturer(s)—name, place of business, and a unique facility identifier—or to include a barcode/QR/link to a searchable electronic portal containing that information. Directs HHS to issue implementing regulations and permits paper copies or package inserts on request.
Who It Affects
Drug manufacturers, contract manufacturers, API suppliers (including foreign firms), packers/distributors, importers, pharmacies and wholesalers that need provenance data for recalls, and the FDA for enforcement and regulation writing.
Why It Matters
It creates a statutory baseline for supply‑chain provenance tied directly to product labeling, improving recall speed and chain‑of‑custody analysis while shifting disclosure and operational burdens onto firms and raising questions about commercial confidentiality and international trade handling.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites the classic manufacturer line on drug labels to require three pieces of provenance: a name, a place of business, and a unique facility identifier (UFI). Firms can either print that trio on the physical label or provide machine‑readable access—barcode, QR code, or link—to a searchable electronic portal that contains the same data.
That flexibility lets companies avoid cluttering small packages but still creates a single public access point for tracing a drug's provenance.
For active pharmaceutical ingredients (APIs), the bill requires that any accompanying label or certificate of analysis include the original manufacturer's name, place, and UFI. For finished drug products, the labeling must identify the original manufacturer of each API used and the original manufacturer of the finished product itself.
If a finished product could be made with APIs from multiple potential manufacturers, the requirement is met by identifying all such manufacturers or by listing them in the portal. The statute defines “original manufacturer” as the single last establishment to carry out substantial manufacturing activities before the ingredient or drug entered interstate commerce—language aimed at cutting through contract‑manufacturing chains but which will raise legal questions in practice.In addition to electronic publication, the bill obliges the manufacturer, packer, or distributor to provide the same information in a package insert or to supply a paper copy on request.
The Secretary of HHS must promulgate regulations to operationalize the API and finished product disclosure rules and may allow reasonable variations or alternative placements of the labeling requirement, including electronic options; those regulations cannot take effect earlier than one year after publication of the final rule and will apply to drugs manufactured on or after the effective date.Finally, the bill amends the Tariff Act to carve out an exception to usual customs country‑of‑origin marking requirements for finished drug products that comply with the new FD&C labeling requirements. Practically, that prevents a conflict between the new provenance disclosures and customs marking law, but it ties trade treatment to compliance with the statute's disclosure standard.
The Five Things You Need to Know
The bill requires name, place of business, and a unique facility identifier (UFI) for the manufacturer, packer, or distributor on drug labels—or a barcode/QR/link to a searchable portal that contains that information.
For active pharmaceutical ingredients, the accompanying label or certificate of analysis must include the original manufacturer's name, place of business, and UFI.
Finished drug labeling must identify the original manufacturer of each API and the original manufacturer of the finished drug product; if multiple potential API manufacturers exist, listing all such manufacturers (or including them in the portal) satisfies the rule.
Manufacturers must make the provenance information available electronically and also in a package insert or paper copy upon request; the statute defines “original manufacturer” as the single last establishment to perform substantial manufacturing steps before interstate commerce.
The Secretary is required to issue implementing regulations (which take effect no sooner than 1 year after final rule publication), and the bill exempts finished drug products labeled under this rule from the Tariff Act’s normal country‑of‑origin marking requirements.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title—CLEAR LABELS Act
Provides the Act's short title: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS Act). This is purely stylistic but signals the bill's policy aim: transparency and accountability for base manufacturers and API reporting.
Changes the manufacturer/packer/distributor line to require a UFI or link to a portal
Replaces the existing single‑phrase manufacturer identification with a requirement for name, place, and a unique facility identifier or a machine‑readable link to a searchable electronic portal containing those fields. That gives manufacturers two compliance paths—physical labeling or digital linking—while making the UFI a statutory element. The UFI requirement creates the expectation of a standardized identifier; the bill leaves the precise format to implementing regulations, which will be critical for interoperability with existing identifiers (e.g., FDA facility IDs, DUNS/UNS).
API and finished drug provenance obligations
Adds explicit obligations for APIs and finished products. For APIs, the bill requires that any accompanying label and certificate of analysis list the original manufacturer's name, place, and UFI. For finished products, labeling must list the original manufacturer of each API, the original manufacturer of the finished product, and the packer/distributor—or provide a portal link containing that data. The text allows listing multiple potential API manufacturers when a product can be made with APIs from several sources, but that will expand disclosure obligations for complex sourcing models.
Access, definition of 'original manufacturer,' and rulemaking
Requires that required information be made available electronically and through package inserts or on paper on request, ensuring access for users without QR readers. It defines “original manufacturer” as the single last establishment to carry out substantial manufacturing activities before introduction into interstate commerce—an operationally significant definition meant to identify a single accountable facility even in contract manufacturing chains. Finally, it directs the Secretary to issue regulations to implement the API and finished product rules, permits reasonable variations or alternative placements (including electronic means), and delays regulatory effectiveness until at least one year after final rule publication and as to drugs manufactured on or after the effective date.
Tariff Act marking exemption tied to compliance
Adds a carve‑out to 19 U.S.C. 1304 so that the usual customs country‑of‑origin marking requirements do not apply to finished drug products that are marked in accordance with the new FD&C labeling rule. The amendment ties customs marking treatment to statutory compliance with the provenance disclosure standard, avoiding direct conflicts between customs marking obligations and the new labeling options (like QR codes or portal links).
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients and clinicians — faster, clearer provenance reduces time to identify sources during recalls or safety investigations, improving patient safety and confidence in medicines.
- FDA and public‑health investigators — labeled UFIs and searchable portals simplify tracebacks, reducing time and resources needed to locate a problematic manufacturer or API lot.
- Pharmacies and hospital supply chains — clearer supplier IDs help inventory decisions, substitution checks, and supplier verification during shortages or quality alerts.
- Importing countries and procurement officers — the standardized disclosure can be used to verify origin and manufacturing accountability during contracting and procurement reviews.
Who Bears the Cost
- Brand companies and contract manufacturers — they must redesign labels or build/maintain searchable portals, update COAs, and track UFI assignment and change control; small and specialty manufacturers will feel disproportionate burdens.
- Foreign API suppliers and subcontractors — the rule may force disclosure of facility identifiers and points of manufacture that firms consider commercially sensitive, creating negotiation, contractual, and legal costs.
- Packers and distributors — additional labeling obligations and the need to coordinate provenance data increases operational complexity and potential liability exposure for mistakes.
- FDA and HHS — the agencies must write technical regulations, set UFI standards, and monitor compliance, creating administrative and enforcement costs that may not be funded in the statute.
Key Issues
The Core Tension
The bill forces a choice between two legitimate goals: the public‑health value of transparent, machine‑readable provenance for rapid tracebacks versus the commercial and security interests of manufacturers who rely on confidentiality, lean supply chains, and complex contract manufacturing—transparency helps regulators and patients but imposes operational, legal, and competitive costs on firms with no clear, costless way to reconcile both aims.
The bill advances a clear policy objective—provenance tied directly to the product—but implementation will surface hard tradeoffs. The statutory requirement for a ‘unique facility identifier’ creates the need for a single, authoritative ID system; the bill leaves the format and issuing authority to HHS rulemaking.
That raises interoperability issues with identifiers already used by industry (e.g., FDA facility establishment identifiers, global company numbers) and questions about whether the UFI will be public or restricted to certain users.
The definition of “original manufacturer” as the last establishment to perform substantial manufacturing activities is operationally precise but practically contentious in contract‑manufacturing arrangements. Companies using multi‑tier contracting, tolling, or partial processing may face disputes about who counts as the original manufacturer, with implications for liability and commercial confidentiality.
Requiring COAs and labels to carry origin data creates a tension with trade‑secret and security concerns: firms may resist disclosing upstream suppliers or facility locations that competitors or bad actors could exploit.
Finally, the searchable portal option solves physical label space limits but introduces information governance issues: who hosts the portal, how data are authenticated, what search capabilities are required, and how to secure access against spoofing or data tampering. The Tariff Act exemption neatly avoids a marking conflict but links customs treatment to compliance with the disclosure standard, potentially complicating customs inspections and international trade reporting if different jurisdictions adopt different provenance expectations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.